UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Group by: Author | Type
Jump to: A | B | C | D | E | G | H | K | L | M | O | P | Q | R | T | W
Number of items: 45.

A

Ainley, L; Chavda, SJ; Counsell, N; Cheesman, S; Newrick, F; Horder, J; Kyriakou, C; ... Yong, K; + view all (2021) DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. British Journal of Haematology , 192 (3) e73-e77. 10.1111/bjh.17248.

Arend, RC; Monk, BJ; Herzog, TJ; Moore, KN; Shapira-Frommer, R; Ledermann, JA; Tewari, KS; ... Penson, RT; + view all (2021) Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecologic Oncology 10.1016/j.ygyno.2021.02.014. (In press).

B

Bachy, E; Rufibach, K; Parreira, J; Launonen, A; Nielsen, T; Hackshaw, A; (2021) Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. Advances in Therapy 10.1007/s12325-021-01738-2. (In press). Green open access
file

Baert, T; Ferrero, A; Sehouli, J; O Donnell, DM; González-Martín, A; Joly, F; Van der Velden, J; ... Ledermann, JA; + view all (2021) The systemic treatment of recurrent ovarian cancer revisited. Annals of Oncology 10.1016/j.annonc.2021.02.015. (In press).

Bentham, R; Litchfield, K; Watkins, TBK; Lim, EL; Rosenthal, R; Martinez-Ruiz, C; Hiley, CT; ... McGranahan, N; + view all (2021) Using DNA sequencing data to quantify T cell fraction and therapy response. Nature 10.1038/s41586-021-03894-5. (In press).

Biasco, L; Izotova, N; Rivat, C; Ghorashian, S; Richardson, R; Guvenel, A; Hough, R; ... Amrolia, PJ; + view all (2021) Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nature Cancer 10.1038/s43018-021-00207-7. (In press).

C

Camilleri, M; Cuadrado, M; Phillips, E; Wilson, W; Jenner, R; Pang, G; Kamora, S; ... Yong, K; + view all (2021) Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British Journal of Haematology 10.1111/bjh.17377. (In press). Green open access
file

Camilleri, M; Sive, J; Wilson, W; Pang, G; Jenner, R; Phillips, E; Popat, R; ... Yong, K; + view all (2021) COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial. British Journal of Haematology , 192 (1) E14-E16. 10.1111/bjh.17168.

Clamp, AR; Lorusso, D; Oza, AM; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; ... Ledermann, JA; + view all (2021) Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International Journal of Gynecological Cancer 10.1136/ijgc-2020-002240. (In press). Green open access
file

Clark, JJ; Dwyer, D; Pinwill, N; Clark, P; Johnson, P; Hackshaw, A; (2021) The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. The Lancet Oncology , 22 (1) pp. 66-73. 10.1016/S1470-2045(20)30619-7. Green open access
file

Concin, N; Creutzberg, CL; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, JA; ... Matias-Guiu, X; + view all (2021) ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv , 478 pp. 153-190. 10.1007/s00428-020-03007-z.

Concin, N; Matias-Guiu, X; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, J; ... Creutzberg, CL; + view all (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal Of Gynecological Cancer , 31 (1) pp. 12-39. 10.1136/ijgc-2020-002230. Green open access
file

Concin, N; Matias-Guiu, X; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, J; ... Creutzberg, CL; + view all (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology , 154 pp. 327-353. 10.1016/j.radonc.2020.11.018.

Cross, AJ; Myles, J; Greliak, P; Hackshaw, A; Halloran, S; Benton, SC; Addison, C; ... Raine, R; + view all (2021) Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial. Journal of Medical Screening 10.1177/0969141321997480. Green open access
file

D

Dettorre, GM; Dolly, S; Loizidou, A; Chester, J; Jackson, A; Mukherjee, U; Zambelli, A; ... OnCovid study group; + view all (2021) Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. Journal for ImmunoTherapy of Cancer , 9 (3) , Article e002277. 10.1136/jitc-2020-002277. Green open access
file

E

Elyashiv, O; Wong, YNS; Ledermann, JA; (2021) Frontline Maintenance Treatment for Ovarian Cancer. Current Oncology Reports , 23 (8) , Article 97. 10.1007/s11912-021-01088-w. Green open access
file

G

Gleeson, M; Counsell, N; Cunningham, D; Lawrie, A; Clifton-Hadley, L; Hawkes, E; McMillan, A; ... Linch, D; + view all (2021) Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. British Journal of Haematology , 192 (6) pp. 1015-1019. 10.1111/bjh.16691. Green open access
file

H

Hackshaw, A; Berg, CD; (2021) An efficient randomised trial design for multi-cancer screening blood tests: nested enhanced mortality outcomes of screening trial. Lancet Oncology , 22 (10) pp. 1360-1362. 10.1016/S1470-2045(21)00204-7.

Hackshaw, A; Cohen, SS; Reichert, H; Kansal, AR; Chung, KC; Ofman, JJ; (2021) Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. British Journal of Cancer 10.1038/s41416-021-01498-4. (In press). Green open access
file

Hoskin, P; Popova, B; Schofield, O; Brammer, C; Robinson, M; Brunt, AM; Madhavan, K; ... Kirkwood, AA; + view all (2021) 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. The Lancet Oncology , 22 (3) pp. 332-340. 10.1016/S1470-2045(20)30686-0. Green open access
file

K

Kurtz, JE; Gebski, V; Sukhin, V; Carey, M; Kong, I; Glasspool, RM; Berek, JS; ... Friedlander, M; + view all (2021) Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecologic Oncology 10.1016/j.ygyno.2021.02.018. (In press).

L

Lacas, B; Carmel, A; Landais, C; Wong, SJ; Licitra, L; Tobias, JS; Burtness, B; ... MACH-NC Collaborative Group; + view all (2021) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology , 156 pp. 281-293. 10.1016/j.radonc.2021.01.013.

Leary, A; Tan, D; Ledermann, J; (2021) Immune checkpoint inhibitors in ovarian cancer: where do we stand? Therapeutic Advances in Medical Oncology , 13 10.1177/17588359211039899. Green open access
file

Ledermann, JA; Embleton-Thirsk, AC; Perren, TJ; Jayson, GC; Rustin, GJS; Kaye, SB; Hirte, H; ... ICON6 collaborators, .; + view all (2021) Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. ESMO Open , 6 (2) , Article 100043. 10.1016/j.esmoop.2020.100043. Green open access
file

Lee, CK; Friedlander, ML; Tjokrowidjaja, A; Ledermann, JA; Coleman, RL; Mirza, MR; Matulonis, UA; ... Scott, CL; + view all (2021) Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer 10.1002/cncr.33517. (In press).

M

Martinez-Calle, N; Kirkwood, AA; Lamb, M; Smith, A; Khwaja, J; Manos, K; Shrubsole, C; ... Fox, CP; + view all (2021) Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy 10.1007/s12325-021-01764-0. Green open access
file

McCulloch, R; Lewis, D; Crosbie, N; Eyre, TA; Bolam, S; Arasaretnam, A; Creasey, T; ... Rule, S; + view all (2021) Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. British Journal of Haematology 10.1111/bjh.17363. Green open access
file

Mikhaeel, NG; Cunningham, D; Counsell, N; McMillan, A; Radford, JA; Ardeshna, KM; Lawrie, A; ... Barrington, SF; + view all (2021) FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. British Journal of Haematology , 192 (3) pp. 504-513. 10.1111/bjh.16875. Green open access
file

Monk, BJ; Colombo, N; Oza, AM; Fujiwara, K; Birrer, MJ; Randall, L; Poddubskaya, EV; ... Ledermann, JA; + view all (2021) Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. The Lancet Oncology , 22 (9) pp. 1275-1289. 10.1016/S1470-2045(21)00342-9.

Morgan, RD; McNeish, IA; Cook, AD; James, EC; Lord, R; Dark, G; Glasspool, RM; ... Clamp, AR; + view all (2021) Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. The Lancet Oncology , 22 (2) pp. 277-288. 10.1016/S1470-2045(20)30591-X. Green open access
filefilefilefilefile

O

Oaknin, A; Oza, AM; Lorusso, D; Aghajanian, C; Dean, A; Colombo, N; Weberpals, JI; ... Coleman, RL; + view all (2021) Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Medicine 10.1002/cam4.4260. (In press). Green open access
file

P

Petit, C; Lacas, B; Pignon, J-P; Le, QT; Grégoire, V; Grau, C; Hackshaw, A; ... MACH-NC and MARCH Collaborative Groups; + view all (2021) Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. Lancet Oncology , 22 (5) pp. 727-736. 10.1016/S1470-2045(21)00076-0.

Pinato, DJ; Scotti, L; Gennari, A; Colomba-Blameble, E; Dolly, S; Loizidou, A; Chester, J; ... Cortellini, A; + view all (2021) Determinants of enhanced vulnerability to COVID-19 in UK cancer patients: a European Study. European Journal of Cancer 10.1016/j.ejca.2021.03.035. (In press).

Popat, R; Counsell, N; de Tute, R; De-Silva, D; Phillips, EH; Cavenagh, JD; Adedayo, T; ... Yong, K; + view all (2021) Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. British Journal of Haematology 10.1111/bjh.17391. (In press).

Poveda, A; Floquet, A; Ledermann, JA; Asher, R; Penson, RT; Oza, AM; Korach, J; ... SOLO2/ENGOT-Ov21 investigators, .; + view all (2021) Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology 10.1016/S1470-2045(21)00073-5. (In press). Green open access
filefile

Pujade-Lauraine, E; Fujiwara, K; Ledermann, JA; Oza, AM; Kristeleit, R; Ray-Coquard, I-L; Richardson, GE; ... Monk, BJ; + view all (2021) Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. The Lancet Oncology , 22 (7) pp. 1034-1046. 10.1016/S1470-2045(21)00216-3.

Q

Quaife, SL; Waller, J; Dickson, JL; Brain, KE; Kurtidu, C; McCabe, J; Hackshaw, A; ... Janes, SM; + view all (2021) Psychological Targets for Lung Cancer Screening Uptake: A Prospective Longitudinal Cohort Study. Journal of Thoracic Oncology 10.1016/j.jtho.2021.07.025. (In press).

R

Rockall, AG; Barwick, TD; Wilson, W; Singh, N; Bharwani, N; Sohaib, A; Nobbenhuis, M; ... Study Group, M; + view all (2021) Diagnostic accuracy of FET-PET/CT, FDG-PET/CT and diffusion-weighted MRI in detection of nodal metastases in surgically treated endometrial and cervical carcinoma. Clinical Cancer Research 10.1158/1078-0432.ccr-21-1834. (In press). Green open access
file

Russell, J; Collins, A; Fowler, A; Karanth, M; Saha, C; Docherty, S; Padayatty, J; ... Follows, GA; + view all (2021) Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Annals of Hematology , 100 pp. 1049-1058. 10.1007/s00277-021-04460-9. Green open access
file

T

Tjokrowidjaja, A; Friedlander, M; Lord, SJ; Asher, R; Rodrigues, M; Ledermann, JA; Matulonis, UA; ... Lee, CK; + view all (2021) Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer , 154 pp. 190-200. 10.1016/j.ejca.2021.06.024.

W

Wall, EC; Wu, M; Harvey, R; Kelly, G; Warchal, S; Sawyer, C; Daniels, R; ... Bauer, DL; + view all (2021) AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. The Lancet 10.1016/S0140-6736(21)01462-8. (In press). Green open access
file

Wall, EC; Wu, M; Harvey, R; Kelly, G; Warchal, S; Sawyer, C; Daniels, R; ... Bauer, DLV; + view all (2021) Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet 10.1016/s0140-6736(21)01290-3. (In press). Green open access
file

Watts, C; Ashkan, K; Jenkinson, MD; Price, SJ; Santarius, T; Matys, T; Zhang, TT; ... Counsell, N; + view all (2021) An evaluation of the tolerability and feasibility of combining 5-amino-levulinic acid (5-ala) with bcnu wafers in the surgical management of primary glioblastoma. Cancers , 13 , Article 3241. 10.3390/cancers13133241. Green open access
file

Wong, Yien Ning Sophia; (2021) Identification of urine derived lymphocytes as a non-invasive measure of the tumour immune microenvironment in bladder cancer. Doctoral thesis (Ph.D), UCL (University College London).

Wood, GE; Ledermann, JA; (2021) Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 10.1016/j.bpobgyn.2021.09.002. (In press).

This list was generated on Wed Oct 13 00:57:26 2021 BST.